|
|
Exchange: |
Nasdaq Small Cap |
Security
Type: |
Common |
Shares
Out: |
15,280,000 |
Market
Cap: |
84.19(M) |
Last
Volume: |
1,505,916 |
Avg
Vol: |
1,501,694 |
52
Week Range: |
$2.25 - $7.96 |
|
Level
I Sector: |
Industrials |
Level
II Sector: |
Diversified Services |
Level
III Sector: |
Research Services |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : 8.6 |
Insider 6 Months : 14.8 |
Insider 3/6 Months : 23.6 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Delcath Systems is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Co.'s primary product candidate, the HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) (HEPZATO), is a drug/device combination product. HEPZATO is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, Co.'s commercial product is a stand-alone medical device having the same device components as the HEZPATO but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT® Hepatic Delivery System for Melphalan.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
53,764 |
357,764 |
382,819 |
561,734 |
Total Buy Value |
$200,002 |
$981,272 |
$1,081,809 |
$1,756,761 |
Total People Bought |
2 |
6 |
8 |
9 |
Total Buy Transactions |
2 |
8 |
10 |
18 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-01-21 |
2023-10-20 |
2023-04-21 |
2022-04-21 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Michel Gerard J |
Chief Executive Officer |
|
2023-03-29 |
4 |
B |
$4.84 |
$95,087 |
D/D |
19,646 |
197,235 |
2.81 |
-27% |
|
Salamon Steven A J |
Director |
|
2022-12-14 |
4 |
B |
$3.62 |
$55,045 |
D/D |
15,215 |
455,315 |
2.39 |
54% |
|
Rosalind Advisors, Inc. |
Director |
|
2022-12-14 |
4 |
B |
$3.62 |
$55,045 |
I/I |
15,215 |
459,315 |
2.1 |
54% |
|
Michel Gerard J |
Chief Executive Officer |
|
2022-12-13 |
4 |
B |
$2.90 |
$150,003 |
D/D |
51,725 |
177,589 |
2.81 |
54% |
|
Michel Gerard J |
Chief Executive Officer |
|
2022-07-20 |
4 |
B |
$3.98 |
$250,000 |
D/D |
62,814 |
125,864 |
2.81 |
-29% |
|
Purpura John |
Chief Operating Officer |
|
2022-05-16 |
4 |
B |
$4.61 |
$15,213 |
D/D |
3,300 |
27,021 |
2.74 |
-30% |
|
Salamon Steven A J |
Director |
|
2022-05-13 |
4 |
B |
$5.03 |
$25,135 |
I/I |
5,000 |
440,100 |
2.1 |
-32% |
|
Salamon Steven A J |
Director |
|
2022-05-12 |
4 |
B |
$4.90 |
$29,424 |
I/I |
6,000 |
29,424 |
2.1 |
-27% |
|
Rosalind Advisors, Inc. |
Director |
|
2022-04-19 |
4 |
B |
$6.25 |
$10,000 |
I/I |
1,600 |
433,100 |
2.1 |
-34% |
|
Salamon Steven A J |
Director |
|
2022-04-19 |
4 |
B |
$6.25 |
$10,000 |
I/I |
1,600 |
429,100 |
2.1 |
-34% |
|
Rosalind Advisors, Inc. |
Director |
|
2022-04-18 |
4 |
B |
$6.35 |
$12,697 |
I/I |
2,000 |
431,500 |
2.1 |
-32% |
|
Aharon Gil |
Director |
|
2022-04-18 |
4 |
B |
$6.35 |
$12,697 |
I/I |
2,000 |
404,000 |
2.1 |
-32% |
|
Michel Gerard J |
See Remarks |
|
2022-04-18 |
4 |
B |
$6.34 |
$12,734 |
D/D |
2,000 |
63,050 |
2.81 |
-32% |
|
Rosalind Advisors, Inc. |
Director |
|
2022-04-13 |
4 |
B |
$6.45 |
$9,675 |
I/I |
1,500 |
429,500 |
2.1 |
-33% |
|
Salamon Steven A J |
Director |
|
2022-04-13 |
4 |
B |
$6.45 |
$9,675 |
I/I |
1,500 |
427,500 |
2.1 |
-33% |
|
Rosalind Advisors, Inc. |
Director |
|
2022-04-12 |
4 |
B |
$6.48 |
$16,200 |
I/I |
2,500 |
428,000 |
2.1 |
-34% |
|
Salamon Steven A J |
Director |
|
2022-04-12 |
4 |
B |
$6.48 |
$16,200 |
I/I |
2,500 |
425,000 |
2.1 |
-34% |
|
Purpura John |
Chief Operating Officer |
|
2022-04-11 |
4 |
B |
$6.59 |
$32,950 |
D/D |
5,000 |
23,721 |
2.74 |
-34% |
|
Michel Gerard J |
See Remarks |
|
2022-04-08 |
4 |
B |
$6.55 |
$13,136 |
D/D |
2,000 |
61,050 |
2.81 |
-33% |
|
Rosalind Advisors, Inc. |
Director |
|
2022-04-07 |
4 |
B |
$6.41 |
$6,410 |
I/I |
1,000 |
425,500 |
2.1 |
-29% |
|
Salamon Steven A J |
Director |
|
2022-04-07 |
4 |
B |
$6.41 |
$6,410 |
I/I |
1,000 |
423,500 |
2.1 |
-29% |
|
Rosalind Advisors, Inc. |
Director |
|
2022-04-06 |
4 |
B |
$6.49 |
$6,490 |
I/I |
1,000 |
424,500 |
2.1 |
-31% |
|
Salamon Steven A J |
Director |
|
2022-04-06 |
4 |
B |
$6.49 |
$6,490 |
I/I |
1,000 |
422,500 |
2.1 |
-31% |
|
Salamon Steven A J |
Director |
|
2021-12-30 |
4 |
B |
$7.56 |
$15,120 |
D/D |
2,000 |
421,500 |
2.39 |
-29% |
|
Rosalind Advisors, Inc. |
Director |
|
2021-12-30 |
4 |
B |
$7.56 |
$15,120 |
I/I |
2,000 |
423,500 |
2.1 |
-29% |
|
44 Records found
|
|
Page 1 of 2 |
|
|